# Traws Pharma, Inc. (TRAW) · Edgar & Edgarette company card

> Traws Pharma, Inc. (TRAW) grew revenue 1135% in FY2025 to $3 million, operating margin -641% against a -3.8% median for pharmaceutical preparations, equity -5.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1130598 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TRAW) · [JSON](https://www.pops4.com/boards/company/TRAW.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3M |
| Revenue growth, 1 year | 1134.5% |
| Revenue growth per year | 87.4% |
| Operating margin | -640.7% (prior year -62997.3%) |
| Net margin | 328.7% |
| Operating cash flow | −$18M |
| Capital spending | $3M |
| Free cash flow | −$21M |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $11M |
| Total equity | −$629,000 |
| Equity ÷ assets | -5.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -209.84 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -640.7% in FY2025; revenue is hard to predict: its 80% range is ±39%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $2.8M (FY2025). Experience: revenue up 1134.5% on the year, up 87.4% a year over 4 years; operating margin -640.7%, up from -62997.3%. Soundness: equity -5.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $13.2M and $30.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $12.5M to $32.1M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -640.7% against a -3.8% median; growth 1134.5% against 13.7%.

Range logged 2026-10-21, receipt 201caf2befcf7431, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1130598/000113059826000002/0001130598-26-000002-index.htm))
- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-07-31 ([filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926089220/0001104659-26-089220-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-07-09 ([filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926082250/0001104659-26-082250-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926128498/0001104659-26-128498-index.htm)
- 8-K · filed 2026-11-16 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926128450/0001104659-26-128450-index.htm)
- 8-K · filed 2026-11-12 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926125797/0001104659-26-125797-index.htm)
- S-1 · filed 2026-10-26 · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926118813/0001104659-26-118813-index.htm)
- 8-K · filed 2026-10-23 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926118519/0001104659-26-118519-index.htm)
- DEF 14A · filed 2026-10-20 · [filing](https://www.sec.gov/Archives/edgar/data/1130598/000110465926117406/0001104659-26-117406-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001130598.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1130598

## Cite

POPS4, Edgar & Edgarette: Traws Pharma, Inc. (TRAW) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/TRAW. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

